source
- Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trialCapricor Therapeutics’ deramiocel cell therapy was rejected for a second time by the FDA on Friday, despite the company's pivot to a narrower indication within Duchenne muscular dystrophy. In aEndpoints · 56m ago↗ source
- Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trialMerck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.